Antimicrobial Resistance
Resistance pathway modeling, target robustness evaluation, and compound novelty screening for AMR programs.
Decision Problems We Address
AMR programs face unique challenges in developing durable antimicrobial therapies
Resistance Pathway Modeling
What are the likely resistance mechanisms for a given antimicrobial target?
Target Robustness
How robust is a target against the evolution of resistance mutations?
Compound Novelty
How structurally novel is a compound relative to existing antimicrobials?
Example Workflow
A typical AMR target evaluation workflow in MedChem
Target Definition
Define antimicrobial targets and their role in pathogen biology.
Resistance Analysis
Model potential resistance mutations and their fitness costs.
Robustness Scoring
Score target robustness based on evolutionary constraints.
Novelty Assessment
Evaluate compound novelty to minimize cross-resistance.
Typical Outputs
MedChem workflows produce comprehensive decision documentation including:
- Resistance mechanism predictions
- Target robustness scores
- Cross-resistance risk assessments
- Compound novelty rankings
- Evolutionary fitness modeling
- Decision documentation with rationale
Limitations
Important to understand what MedChem does not claim:
- Does not guarantee clinical success
- Based on current understanding of resistance
- Requires expert microbiological review
- Not a substitute for in vitro/in vivo testing
Explore AMR Solutions
See how MedChem can support your antimicrobial resistance program decisions.